OABI News & Events

Virtual Meeting to be held to announce the company launches its new product, OmniUltra on December 15 at 5 pm hosted by Craig-Hallum.

OmniAb signied a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG, a joint venture between ArrowMark and Viking Global Investors. OmniAb will receive revenue for services performed as well as potential equity and royalties for the discovery of novel antibodies for targets defined by Mabtrx. ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. Founded in 1999, Viking Global Investors is a global investment firm with a long-term, fundamental, research-intensive approach to investing. Viking manages over $55B of capital across public and private investments.

OmniAb now expects 2025 revenue to be in the range of $18 million to $22 million, and operating expense to be in the range of $82 million to $86 million. In addition, OmniAb continues to expect 2025 cash use to be lower than cash use in 2024, excluding financings. The Company expects to end the year with cash between $52 million and $56 million. The 2025 full year effective tax rate is expected to be approximately 0%.